BACKGROUND: Several studies have suggested that low 25(OH) vitamin D3 levels may be prognostic in some malignancies, but no studies have evaluated their impact on treatment outcome in patients with acute myeloid leukemia (AML). METHODS: Vitamin D levels were evaluated in 97 consecutive, newly diagnosed, intensively treated patients with AML. MicroRNA expression profiles and single nucleotide polymorphisms (SNPs) in the 25(OH) vitamin D3 pathway genes were evaluated and correlated with 25(OH) vitamin D3 levels and treatment outcome. RESULTS: Thirty-four patients (35%) had normal 25(OH) vitamin D3 levels (32-100 ng/mL), 34 patients (35%) had insufficient levels (20-31.9 ng/mL), and 29 patients (30%) had deficient levels (<20 ng/mL). Insufficient/deficient 25(OH) vitamin D3 levels were associated with worse relapse-free survival (RFS) compared with normal vitamin D3 levels. In multivariate analyses, deficient 25(OH) vitamin D3 , smoking, European Leukemia Network genetic group, and white blood cell count retained their statistical significance for RFS. Several microRNAs and SNPs were associated with 25(OH) vitamin D3 levels, although none remained significant after multiple test corrections; one 25(OH) vitamin D3 receptor SNP, rs10783219, was associated with a lower complete remission rate (P = .0442) and with shorter RFS (P = .0058) and overall survival (P = .0011). CONCLUSIONS: It remains to be determined what role microRNA and SNP profiles play in contributing to low 25(OH) vitamin D3 level and/or outcome and whether supplementation will improve outcomes for patients with AML.
BACKGROUND: Several studies have suggested that low 25(OH) vitamin D3 levels may be prognostic in some malignancies, but no studies have evaluated their impact on treatment outcome in patients with acute myeloid leukemia (AML). METHODS:Vitamin D levels were evaluated in 97 consecutive, newly diagnosed, intensively treated patients with AML. MicroRNA expression profiles and single nucleotide polymorphisms (SNPs) in the 25(OH) vitamin D3 pathway genes were evaluated and correlated with 25(OH) vitamin D3 levels and treatment outcome. RESULTS: Thirty-four patients (35%) had normal 25(OH) vitamin D3 levels (32-100 ng/mL), 34 patients (35%) had insufficient levels (20-31.9 ng/mL), and 29 patients (30%) had deficient levels (<20 ng/mL). Insufficient/deficient25(OH) vitamin D3 levels were associated with worse relapse-free survival (RFS) compared with normal vitamin D3 levels. In multivariate analyses, deficient 25(OH) vitamin D3 , smoking, European Leukemia Network genetic group, and white blood cell count retained their statistical significance for RFS. Several microRNAs and SNPs were associated with 25(OH) vitamin D3 levels, although none remained significant after multiple test corrections; one 25(OH)vitamin D3 receptor SNP, rs10783219, was associated with a lower complete remission rate (P = .0442) and with shorter RFS (P = .0058) and overall survival (P = .0011). CONCLUSIONS: It remains to be determined what role microRNA and SNP profiles play in contributing to low 25(OH) vitamin D3 level and/or outcome and whether supplementation will improve outcomes for patients with AML.
Authors: C Miyaura; E Abe; T Kuribayashi; H Tanaka; K Konno; Y Nishii; T Suda Journal: Biochem Biophys Res Commun Date: 1981-10-15 Impact factor: 3.575
Authors: Susan P Whitman; Kati Maharry; Michael D Radmacher; Heiko Becker; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Yue-Zhong Wu; Sebastian Schwind; Klaus H Metzeler; Jing Wen; Maria R Baer; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Joseph O Moore; Richard M Stone; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: Blood Date: 2010-07-23 Impact factor: 22.113
Authors: Haifa A Al-Turki; Mir Sadat-Ali; Abdulmohsen H Al-Elq; Fathma A Al-Mulhim; Amein K Al-Ali Journal: Saudi Med J Date: 2008-12 Impact factor: 1.484
Authors: Araba A Adjei; Bianca A Thomae; Janel L Prondzinski; Bruce W Eckloff; Eric D Wieben; Richard M Weinshilboum Journal: Br J Pharmacol Date: 2003-08 Impact factor: 8.739
Authors: A Grande; R Manfredini; M Pizzanelli; E Tagliafico; R Balestri; F Trevisan; D Barbieri; C Franceschi; R Battini; S Ferrari; S Ferrari Journal: Cell Death Differ Date: 1997-08 Impact factor: 15.828
Authors: Sarah-Michelle Orton; Andrew P Morris; Blanca M Herrera; Sreeram V Ramagopalan; Matthew R Lincoln; Michael J Chao; Reinhold Vieth; A Dessa Sadovnick; George C Ebers Journal: Am J Clin Nutr Date: 2008-08 Impact factor: 7.045
Authors: B Salvatori; I Iosue; A Mangiavacchi; G Loddo; F Padula; S Chiaretti; N Peragine; I Bozzoni; F Fazi; A Fatica Journal: Cell Death Dis Date: 2012-10-25 Impact factor: 8.469
Authors: James Wang; Kyle A Udd; Aleksandra Vidisheva; Regina A Swift; Tanya M Spektor; Eric Bravin; Emad Ibrahim; Jonathan Treisman; Mohammed Masri; James R Berenson Journal: Support Care Cancer Date: 2016-02-23 Impact factor: 3.603
Authors: Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran Journal: J Steroid Biochem Mol Biol Date: 2017-07-20 Impact factor: 4.292
Authors: Paige M Kulling; Kristine C Olson; Thomas L Olson; David J Feith; Thomas P Loughran Journal: Eur J Haematol Date: 2016-11-21 Impact factor: 2.997
Authors: Eric M Ammann; Matthew T Drake; Bjarni Haraldsson; Robert B Wallace; Karen C Johnson; Pinkal Desai; Emily M Lin; Brian K Link Journal: Cancer Date: 2017-06-27 Impact factor: 6.860